CARDIOR

Cardior is focused on the development and clinical validation of ncRNA therapeutics for patients with myocardial infarction and heart failure. Cardior aims to market its products in collaboration with a strategic pharma partner after clinical proof-of-concept (POC) data.

Press releases

Press
25. August 2021

Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease

Oversubscribed round enables late-stage clinical development of lead candidate, a micro-RNA-132 inhibitor, in heart failure and further accelerates pipeline expansion Hanover, Germany, August 25, 2021 – Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, announced today the closing of a €64 million ($76 million) Series B financing round. The round was led by Inkef Capital, supported by fello
 
Press
11. May 2017
Cardior Pharmaceuticals raises €15 million to develop first-in-class ncRNA therapeutics and diagnostics for patients with myocardial infarction and heart failure
Cardior Pharmaceuticals, a spin-off from Hannover Medical School (MHH), today announced the completion of a €15 million Series A financing round led by LSP (Life Sciences Partners), Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS), BioMedPartners (with its new BioMedInvest III Fund) and High-Tech Gründerfonds (HTGF). Cardior is pioneering its proprietary RNA technology to revolutionize predicting and treating heart failure. The molecular targets are non-coding RNAs linked
 

Info & Contact

Dr. Claudia Ulbrich
Web:
www.cardior.de

Address

Cardior Pharmaceuticals GmbH
Carl-Neuberg-Str. 1
30625 Hannover

In portfolio

03. May 2017

HTGF Manager

 
Dr. Frank Hensel, Principal / Authorized signatory